AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
Study NCT03286075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Cathode session
Description: The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system).
Study NCT03286075 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS Placebo session
Description: This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)
Study NCT01951456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Study NCT01951456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Study NCT00315029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence based decision aid
Description: evidence based decision aid
Study NCT00315029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Possible reimbursement 4th IVF/ICSI cycle when necessary
Description: Potential reimbursement 4th IVF/ICSI cycle when necessary
Study NCT03096990 — intervention group
Intervention type: DRUG
Intervention: apremilast
Description: Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
Study NCT04548050 — intervention group
Intervention type: OTHER
Intervention: Nurses training
Description: * Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation.
Study NCT01703312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drug administered by subcutaneous injection
Study NCT00787735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling compliance
Description: Rates of attendance to call counseling session over specific time points
Study NCT00787735 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling compliance
Description: Rates of attendance to call counseling session over specific time points
Study NCT03514225 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metacognitive Therapy for Social Anxiety
Description: The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
Study NCT02407015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo 3DS gameplay
Study NCT01805115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Study NCT01805115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Study NCT01805115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Description: Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
Study NCT01805115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group was not given any cervical priming agents or placebo.
Study NCT02639559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Study NCT02639559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Study NCT02639559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant
Study NCT00772967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study NCT00772967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study NCT02170012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: 20 mg tablet once daily dosing for 14 days
Study NCT02170012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet once daily dosing for 14 days
Study NCT02170012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06743649
Description: To be decided dose, tablet once daily dosing for 14 days
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100μg
Description: Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 150μg
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
Study NCT04539899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR+
Description: Use of a virtual reality helmet during IUD insertion
Study NCT02609633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® CONNECT DMS
Description: SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
Study NCT02609633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DMS
Description: SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
Study NCT00200083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcend II Model 8848
Description: All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up.
Study NCT00200083 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcend II Model 8848
Description: All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up.
Study NCT03203512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil capsules
Description: Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
Study NCT03203512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-oleic safflower oil capsules
Description: High-oleic safflower oil capsules for 12 weeks
Study NCT01189890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
Study NCT01189890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
Study NCT01189890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Matching placebo tablets to sitagliptin to allow for blinding.
Study NCT00858052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline-filled breast implant [IDEAL IMPLANT (R)]
Description: Breast augmentation
Study NCT01604031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-CLL Vaccine
Description: Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
Study NCT01604031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
Study NCT04614779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN128 Tablets
Description: Iron chelator, oral tablets
Study NCT02917499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial magnetic stimulation
Study NCT00741949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation in TCI with propofol
Study NCT00741949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline solution infusion
Study NCT02993302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1α-D3
Description: patients were given PTU and 1α-D3
Study NCT00772967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultracet
Description: Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study NCT04298346 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02238613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radioactive stent
Description: radioactive stent carrying seed iodine 125
Study NCT02238613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: plastic stent
Description: common plastic stent without carrying seed iodine 125
Study NCT01483404 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement with O2c
Description: Intra-surgery measurement of the microcirculation with the O2c device
Study NCT01362322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM (new syringe presentation)
Description: Single dose, intramuscular administration in a new syringe presentation
Study NCT01362322 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix TM (previous syringe presentation)
Description: Single dose, intramuscular administration in previous syringe presentation
Study NCT02552407 — intervention group
Intervention type: DEVICE
Intervention: Manual Aspiration Thrombectomy
Description: Thrombus aspiration
Study NCT02993302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: patients were given PTU and placebos
Study NCT01698008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Doctor Mobile app
Description: Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
Study NCT03709589 — intervention group
Intervention type: OTHER
Intervention: Modified Early Warning Score
Description: Modified Early Warning Score
Study NCT02567292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk
Description: Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
Study NCT03436420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene
Description: Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
Study NCT01159353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
Study NCT01159353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
Study NCT04574700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee joint mobilization and traction
Description: Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks
Study NCT04711187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 1
Description: AT-527 Formulation 1 (R07496998)
Study NCT04711187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo Comparator
Study NCT04711187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 Formulation 2
Description: AT-527 Formulation 2 (R07496998)
Study NCT03944746 — intervention group
Intervention type: OTHER
Intervention: Education Curriculum
Description: Different educational curriculums were applied to each cohort
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 175μg
Description: Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 200μg
Description: Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
Study NCT04574700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post isometric relaxation
Description: Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks.
Study NCT00003812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00003812 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.1 Lucinactant
Description: 3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 300μg
Description: Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 50/72μg
Description: MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 72/125μg
Description: MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100/150μg
Description: MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125/150μg
Description: MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Study NCT02055547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
Study NCT00215553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: B.3 SoC
Description: Standard ARDS management and ICU care
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.2 Lucinactant
Description: 3 30 mL aliquots at a concentration of 10 mg/mL each
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.3 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A.4 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B.1 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL
Study NCT00215553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B.2 Lucinactant
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Study NCT01189890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Glimepiride
Description: Matching placebo tablets to glimepiride to allow for blinding.
Study NCT03198793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001
Description: Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]) over 8 weeks.
Study NCT03356561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 5*10^10 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
Study NCT03356561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 1*10^11 vp
Description: Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.